Suven Life Sciences has secured patents in Australia, Canada, Japan and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action - H3 Inverse agonist and these patents are valid until 2030. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders such as Alzheimer’s, ADHD, dementia, depression, Huntington's disease and Parkinson’s disease. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes. Novel, potent, selective, brain penetrant and orally active H 3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.
With these new patents, Suven has a total of 20 granted patents from Australia, 17 granted patents from Canada, 15 granted patents from Japan and 22 granted patents from New Zeland. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
Suven Life Sciences is currently trading at Rs. 242.50, up by 4.20 points or 1.76% from its previous closing of Rs. 238.30 on the BSE.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders such as Alzheimer’s, ADHD, dementia, depression, Huntington's disease and Parkinson’s disease. H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes. Novel, potent, selective, brain penetrant and orally active H 3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.
With these new patents, Suven has a total of 20 granted patents from Australia, 17 granted patents from Canada, 15 granted patents from Japan and 22 granted patents from New Zeland. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
Suven Life Sciences is currently trading at Rs. 242.50, up by 4.20 points or 1.76% from its previous closing of Rs. 238.30 on the BSE.
No comments:
Post a Comment